In addition, our data reveal the following key findings: (1) targeting Skp2 promotes apoptosis, cell cycle arrest, and inhibits cancer stemness, contributing to a survival benefit in DKO OS; and (2) Small-molecule SKP2 inhibitors are effective in a preclinical setting against Rb/p53-deficient OS and exhibit synergy with conventional chemotherapy. Here, RB1 is linked to cancer.